Institutional Corruption and Pharmaceutical Policy<\/a>
An Edmond J. Safra Center Symposium <\/font><\/strong>
Harvard University<\/font><\/strong>
Journal of Law, Medicine and Ethics <\/font><\/strong>
Vol. 14, No. 3 (2013)<\/div>\n
An Edmond J. Safra Center Symposium <\/font><\/strong>
Harvard University<\/font><\/strong>
Journal of Law, Medicine and Ethics <\/font><\/strong>
Vol. 14, No. 3 (2013)<\/div>\n
<\/p>\n
- \n
- \nMarc Rodwin, Institutional Corruption and Pharmaceutical Policy<\/a><\/em><\/div>\n<\/li>\n
- \n
Lawrence Lessig, Foreword: ‘Institutional Corruption’ Defined<\/em><\/a><\/div>\n<\/li>\n- \n
Gregg Fields, Parallel Problems: Applying Institutional Corruption Analysis of Congress to Big Pharma
<\/em><\/a><\/div>\n<\/li>\n<\/ul>\n1. SYSTEMIC PROBLEMS<\/font><\/strong><\/div>\n- \n
- \nPaul D. Jorgensen, Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda<\/em><\/a><\/div>\n<\/li>\n
- \n
Marc-Andr\u00e9 Gagnon, Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health<\/em><\/a><\/div>\n<\/li>\n- \n
Marc A. Rodwin, Five Un-Easy Pieces of Pharmaceutical Policy Reform<\/em><\/a><\/div>\n<\/li>\n- \n
Donald W. Light, Joel Lexchin, Jonathan J. Darrow, Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs<\/em><\/a><\/div>\n<\/li>\n- \n
Jennifer E. Miller, From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices Through Accreditation, Certification, and Rating<\/em><\/a><\/div>\n<\/li>\n<\/ul>\n2. MEDICAL RESEARCH<\/font><\/strong><\/div>\n- \n
- \nAbigail B. Brown, Understanding Pharmaceutical Research Manipulation in the Context of Accounting Manipulation<\/em><\/a><\/div>\n<\/li>\n
- \n
Yuval Feldman, Rebecca L. Gauthier, and Troy H. Schuler, Curbing Misconduct in the Pharmaceutical Industry: Insights from Behavioral Ethics and the Behavioral Approach to Law<\/em><\/a><\/div>\n<\/li>\n- \n
Garry C. Gray, The Ethics of Pharmaceutical Research Funding: A Social Organization Approach<\/em><\/a><\/div>\n<\/li>\n<\/ul>\n3. MEDICAL KNOWLEDGE AND PRACTICE<\/font><\/strong><\/div>\n- \n
- \nSergio Sismondo, Key Opinion Leaders and the Corruption of Medical Knowledge: What the Sunshine Act Will and Won’t Cast Light On<\/em><\/a><\/div>\n<\/li>\n
- \n
Lisa Cosgrove and Emily E. Wheeler, Drug Firms, the Codification of Diagnostic Categories, and Bias in Clinical Guidelines<\/em> <\/a><\/div>\n<\/li>\n- \n
Marc A. Rodwin, Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use<\/em><\/a><\/div>\n<\/li>\n<\/ul>\n4. MARKETING<\/font><\/strong><\/div>\n- \n
- \nSunita Sah and Adriane Fugh-Berman, Physicians Under the Influence: Social Psychology and Industry Marketing Strategies<\/em><\/a><\/div>\n<\/li>\n
- \n
Amy Snow Landa and Carl Elliott, From Community to Commodity: The Ethics of Pharma-Funded Social Networking Sites for Physicians<\/em><\/a><\/div>\n<\/li>\n<\/ul>\n - \n
- \n
- \n
- \n
- \n
![](\"http:\/\/1boringoldman.com\/images\/hat-tip.gif\")
<\/p>\n","protected":false},"excerpt":{"rendered":"